Research programme: anticancer antibodies - AstraZeneca/AmgenAlternative Names: 2.6.1; 3.19.3; AZD5180
Latest Information Update: 05 May 2009
At a glance
- Originator Amgen; AstraZeneca
- Class Monoclonal antibodies
- Mechanism of Action Angiogenesis inhibitors; ERBB 2 receptor antagonists; Immunostimulants; Urokinase plasminogen activator receptor antagonists; Vascular endothelial growth factor receptor antagonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Preclinical Cancer